Family First, which provides employers and health insurers with a technology platform to support the mental health and wellbeing of caregivers, secured $11 million in Series A funding.
RPM Ventures and Eos Venture Partners led the round with participation from Stephen Fromm and Wormhole Capital.
“Family First takes a holistic, expert approach to solving care challenges,” said Jonathan Kalman, founding partner of Eos Venture Partners, in a statement. “And Family First’s leadership has the proven expertise and track record of scaling such an expert solution.”
Mental health startup UpLift announced that it has raised $10.7 million in Series A funding for total proceeds of $22 million.
New investor Ballast Point Ventures led the round with participation from Front Porch Ventures, Kapor Capital and existing investor B Capital.
The company will use the funds to expand its reach.
“We have long been interested in investing in the behavioral health part of the healthcare industry, particularly as we have seen access to mental health services become even more difficult during the pandemic,” said Matt Rice, partner at Ballast Point Ventures, in a statement. “We are inspired by UpLift’s team-based approach to care, which blends therapy with psychiatry, and look forward to supporting Kyle Talcott and his amazing team on their mission to improve access to affordable care that patients can trust.”
CathVision, a medical technology company focused on electrophysiology solutions for clinical decision making, received $9 million in funding for total proceeds of $30 million.
The Denmark-based company will use the funds to advance the rollout of its ECGenius system, which consists of EP recording technology, and the development of Cardialytics, its AI-powered analytics offering.
The money will also support the development of AI-powered analytics modules to provide data to providers of cardiac ablation procedures and will help expand its sales team and U.S. presence
“Despite challenging times in the financial markets, CathVision remains a confident investment for stakeholders as we meet important milestones that validate the need for our technology, generation of revenue through successful commercialization and our commitment to continued research and development,” said Mads Matthiesen, CEO of CathVision, in a statement. “This investment round will help accelerate commercial rollout through 2024 as we position CathVision to be instrumental in how we help physicians across the United States more effectively treat cardiac arrhythmias.”
